Trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Phase 2/3 trial of whether ctDNA detection after resection of stage IIA colon cancer identifies patients who benefit from adjuvant chemotherapy. ClinicalTrials.gov lists the study as active, not recruiting.
NRG Oncology
Phase 2 study that changes capecitabine, CAPOX, or FOLFIRI according to serial ctDNA after surgery for microsatellite-stable stage III or T4N0 stage II colon cancer. ClinicalTrials.gov lists the status as unknown.
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational study of serial tumor-informed ctDNA after surgery for stage I to IV colorectal cancer, with clinician-directed therapy. ClinicalTrials.gov lists the status as unknown.
Natera, Inc.
Phase 3 randomized trial of trifluridine/tipiracil versus placebo in patients with resected colorectal cancer who test ctDNA-positive without radiographic recurrence. ClinicalTrials.gov lists the study as completed.
National Cancer Center Hospital East
Phase 2/3 trial that assigns adjuvant chemotherapy according to whether circulating tumor DNA is detected after surgery for colon cancer. ClinicalTrials.gov lists the study as recruiting.
NRG Oncology
Randomized trial comparing ctDNA-guided adjuvant therapy with standard adjuvant therapy after radical resection of pancreatic cancer. ClinicalTrials.gov lists the study as recruiting, with a start date of June 1, 2025.
Ruijin Hospital
Interventional study of serial ctDNA in hepatocellular carcinoma and in colorectal cancer metastatic to the liver. The registry lists the phase as not applicable and the primary outcome as assessment of the clinical value of the ctDNA level. ClinicalTrials.gov lists the study as recruiting.
Medical University of Warsaw
NCT07823322 (NEXERA-204) is an Incyte-sponsored, not-yet-recruiting, single-arm phase 2 study of INCA33890 in about 40 adults with Signatera-positive, microsatellite-stable stage II/III colorectal cancer after curative resection and chemotherapy, with ctDNA clearance at 3 months as the primary endpoint; Natera announced a clinical collaboration on this study on November 10, 2026.
Incyte Corporation
NCT07927998 (PACER) is a recruiting, single-arm phase 2 MSK trial (estimated enrollment 25) of retifanlimab after definitive chemoradiation in people with anal squamous cell carcinoma who remain Signatera-positive, with the rate of ctDNA clearance at 12 weeks as the primary endpoint.
Memorial Sloan Kettering Cancer Center